PINC gene delivery systems - Valentis

Drug Profile

PINC gene delivery systems - Valentis

Latest Information Update: 21 May 2007

Price : $50

At a glance

  • Originator Valentis
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 24 Apr 2007 This technology is available for sale or licensing (
  • 13 Apr 2000 New profile
  • 13 Apr 2000 Phase-II clinical trials for Undefined in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top